Literature DB >> 2778713

A stereoselective central hypotensive action of atenolol.

A A Pearson1, T E Gaffney, T Walle, P J Privitera.   

Abstract

Previous studies have demonstrated that propranolol can lower arterial pressure through an action within the central nervous system. The purpose of this study was to determine 1) whether the hydrophilic beta blocking drug atenolol which is devoid of membrane stabilizing activity can reduce arterial pressure through a central action and 2) whether this action is stereoselective for the (-)-, or beta receptor blocking enantiomer. Studies were conducted in the anesthetized spontaneously hypertensive (SH) rats in which the cardiovascular effects of (-)- and (+)- atenolol were compared after i.v. or intracisternal administration. Intravenous injection of 100 micrograms/kg of (-)-atenolol reduced mean arterial pressure 25 +/- 5 mm Hg (P less than .02) and lowered heart rate 58 +/- 7 bpm (P less than .02). The same dose of (+)-atenolol i.v. produced no significant changes in either mean arterial pressure or heart rate. Similarly, intracisternal (-)-atenolol, 66 micrograms/kg, significantly (P less than .05) reduced mean arterial pressure and heart rate whereas the same dose of the (+)-isomer was without effect. When the i.v. dose of (-)-atenolol was lowered to 33 micrograms/kg, heart rate was decreased markedly but mean arterial pressure was not reduced. In contrast, 33 micrograms/kg of intracisternal (-)- atenolol significantly reduced mean arterial pressure 17 +/- 6 mm Hg and reduced heart rate. These results suggest that atenolol possesses a central hypotensive action that is selective for the (-)-, beta receptor blocking enantiomer.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2778713

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  5 in total

1.  Monitoring the effects of chiral pharmaceuticals on aquatic microorganisms by metabolic fingerprinting.

Authors:  Emma S Wharfe; Catherine L Winder; Roger M Jarvis; Royston Goodacre
Journal:  Appl Environ Microbiol       Date:  2010-01-29       Impact factor: 4.792

2.  Propranolol and atenolol inhibit norepinephrine spillover rate into plasma in conscious spontaneously hypertensive rats.

Authors:  T K Keeton; A M Biediger
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-07       Impact factor: 3.000

3.  Revisiting atenolol as a low passive permeability marker.

Authors:  Xiaomei Chen; Tim Slättengren; Elizabeth C M de Lange; David E Smith; Margareta Hammarlund-Udenaes
Journal:  Fluids Barriers CNS       Date:  2017-10-31

Review 4.  Progress in the Enantioseparation of β-Blockers by Chromatographic Methods.

Authors:  Yiwen Yang; Yehui Wang; Zongbi Bao; Qiwei Yang; Zhiguo Zhang; Qilong Ren
Journal:  Molecules       Date:  2021-01-17       Impact factor: 4.411

5.  Design, Development and Optimization of S (-) Atenolol Floating Sustained Release Matrix Tablets Using Surface Response Methodology.

Authors:  P T Gunjal; M B Shinde; V S Gharge; S V Pimple; M K Gurjar; M N Shah
Journal:  Indian J Pharm Sci       Date:  2015 Sep-Oct       Impact factor: 0.975

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.